This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Sign In or Create an Account
or View more offersArticle content
To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit: https://ibn.fm/HOCTP
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
Today’s multiple sclerosis (“MS”) treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control.
Article contentArticle content
That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed not to calm the immune system but to shield, and potentially rebuild, the myelin sheath itself. The clearance sets up what would be the first time in history that a drug built on this exact mechanism gets tested in people living with MS, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts.
Article content
About Quantum BioPharma Ltd.
Article content
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
For further information, please visit the company’s website at www.QuantumBioPharma.com.
Article content
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Article content
About BioMedWire
Article content
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.